Search results for " Administration"

showing 10 items of 4299 documents

ENTERAL NUTRITION SUPPORT TO TREAT MALNUTRITION IN INFLAMMATORY BOWEL DISEASE

2015

Malnutrition is a common consequence of inflammatory bowel disease (IBD). Diet has an important role in the management of IBD, as it prevents and corrects malnutrition. It is well known that diet may be implicated in the aethiology of IBD and that it plays a central role in the pathogenesis of gastrointestinal tract disease. Often oral nutrition alone is not sufficient in the pathogenesis of gastrointestinal tract disease. Often oral nutrition alone is not sufficient in the management of IBD patients, especially in children or elederly, and must be combined with oral supplementation or replaced with tube enteral nutrition. In this review, we describe several different approaches to enteral …

medicine.medical_specialtySettore MED/07 - Microbiologia E Microbiologia ClinicaInflammatory Bowel Diseases IBD enteral feeding mulnutrition dysbiosis dismicrobism home enteral nutritionNutritional Statuslcsh:TX341-641ReviewDiseaseClinical nutritionInflammatory bowel diseaseEnteral administrationEnteral Nutritioninflammatory bowel diseasemedicineHumansDisease management (health)tube feedingIntensive care medicineSettore MED/12 - GastroenterologiaNutrition and Dieteticsbusiness.industryMalnutritionDisease ManagementInflammatory Bowel Diseasesmedicine.diseasedigestive system diseasesMalnutritionSettore MED/18 - Chirurgia GeneraleParenteral nutritionhome enteral nutritionEtiologyenteral feedingnutrients supplementationbusinesslcsh:Nutrition. Foods and food supplyFood Science
researchProduct

US Food and Drug Administration's Risk Evaluation and Mitigation Strategy for Extended-Release and Long-Acting Opioids Pros and Cons, and a European …

2012

Prescriptions for opioid analgesics to manage moderate-to-severe chronic non-cancer pain have increased markedly over the last decade. An unintentional consequence of greater prescription opioid utilization has been the parallel increase in misuse, abuse and overdose, which are serious risks associated with all opioid analgesics. In response to disturbing rises in prescription opioid abuse, the US Food and Drug Administration (FDA) has proposed the implementation of aggressive Risk Evaluation and Mitigation Strategies (REMS). While REMS could dramatically change the development, release, marketing and prescription of extended-release opioids, questions remain on how these programmes may inf…

medicine.medical_specialtyTime FactorsSettore MED/41 - AnestesiologiaLong-Acting Opioids Food and drug administration AnalgesiaRisk AssessmentFood and drug administrationPatient safetyPharmacotherapymedicineHumansPharmacology (medical)Medical prescriptionIntensive care medicineUnited States Food and Drug Administrationbusiness.industryPerspective (graphical)Chronic painLong-Acting Opioids Food and drug administration AnalgesiaOpioid-Related Disordersmedicine.diseaseUnited StatesRisk evaluationAnalgesics OpioidEuropeDelayed-Action PreparationsMedical emergencyChronic PainRisk assessmentbusiness
researchProduct

How should we determine length of anticoagulation after proximal deep vein thrombosis of the lower limbs?

2009

The current approach for deciding the duration of vitamin K antagonist (VKA) treatment after an episode of venous thrombo-embolism (VTE) is mainly based on the characteristic of the index event (3 months or longer in case of unknown/persistent risk factors, 3 months or less in case of removable causes). However, the length of anticoagulation should be tailored on the patient's risk for recurrent thrombosis as well as for bleeding, but such 'time for decision' is often unclear and the optimal duration of VKA remains debatable. The presence of persistent residual vein thrombosis and increased D-dimer levels after stopping therapy are predictors for recurrent deep vein thrombosis (DVT). Manage…

medicine.medical_specialtyTime FactorsVitamin Kmedicine.drug_classDeep veinRisk AssessmentDrug Administration ScheduleRecurrent deep vein thrombosisSettore MED/15 - Malattie Del SangueFibrin Fibrinogen Degradation ProductsFibrinolytic AgentsRecurrenceNeoplasmsmedicineHumansVenous ThrombosisFirst episodebusiness.industryVascular diseaseAnticoagulantVitaminsHematologyVitamin K antagonistmedicine.diseaseThrombosisduration anticoagulants venous thromboembolismSurgeryVenous thrombosismedicine.anatomical_structurebusinessBiomarkersBritish Journal of Haematology
researchProduct

Evaluation of low-dose metronomic (LDM) cyclophosphamide toxicity in cats with malignant neoplasia

2014

Oral administration of low-dose cyclophosphamide in pets with spontaneously occurring malignant neoplasms has become a common practice in veterinary medicine. The purpose of this retrospective study was to investigate toxicity events in cats with spontaneous malignancies receiving cyclophosphamide as a metronomic therapy for at least 1 month. The number and severity of clinical, haematological and biochemical adverse events were recorded according to the Veterinary Cooperative Oncology Group’s Common Terminology Criteria for Adverse Events v1.1 classification scheme. Twenty-four cats were enrolled in the study with a total number of 27 neoplasms: 13 sarcomas, 12 carcinomas, one melanoma an…

medicine.medical_specialtyToceranibCyclophosphamideCat DiseasesGastroenterologyDisease-Free SurvivalDrug Administration ScheduleMetastasisNeoplasmsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineAnimalsSmall AnimalsAdverse effectAntineoplastic Agents AlkylatingCyclophosphamideNeoplasm StagingRetrospective StudiesCATSDose-Response Relationship Drugbusiness.industryCommon Terminology Criteria for Adverse Eventsmedicine.diseaseSurgeryThalidomideToxicityCatsbusinessmedicine.drugJournal of Feline Medicine and Surgery
researchProduct

A common mechanism of action of the selective serotonin reuptake inhibitors citalopram and fluoxetine: Reversal of chronic psychosocial stress-induce…

2010

The transcription factor CREB regulates adaptive responses like memory consolidation, addiction, and synaptic refinement. Recently, chronic psychosocial stress as animal model of depression has been shown to stimulate CREB transcriptional activity in the brain; this stimulation was prevented by treatment with the antidepressant imipramine, which inhibits both noradrenaline and serotonin reuptake. However, it was unknown whether the selective inhibition of serotonin reuptake is sufficient for inhibition of stress-induced CREB activation, as it is for the clinical antidepressant effect. Therefore, the effect of two selective serotonin reuptake inhibitors (SSRIs), citalopram and fluoxetine, wa…

medicine.medical_specialtyTranscription GeneticMice TransgenicCitalopramBiologyCitalopramCREBImipramineDrug Administration ScheduleMice03 medical and health sciences0302 clinical medicineGenes ReporterCREB in cognitionFluoxetineInternal medicinemedicineAnimalsPhosphorylationCyclic AMP Response Element-Binding ProteinTranscription factor030304 developmental biologyPharmacology0303 health sciencesFluoxetineBrain3. Good healthEndocrinologyGene Expression RegulationMechanism of actionbiology.proteinAntidepressantmedicine.symptomSelective Serotonin Reuptake InhibitorsStress Psychological030217 neurology & neurosurgerymedicine.drugEuropean Journal of Pharmacology
researchProduct

S2k guidelines for the treatment of psoriasis in children and adolescents - Short version part 2.

2019

The present guidelines are aimed at residents and board-certified physicians in the fields of dermatology, pediatrics, pediatric dermatology and pediatric rheumatology as well as policymakers and insurance funds. They were developed by dermatologists and pediatric dermatologists in collaboration with pediatric rheumatologists using a formal consensus process (S2k). The guidelines highlight topics such as disease severity, quality of life, treatment goals as well as problems associated with off-label drug therapy in children. Trigger factors and diagnostic aspects are discussed. The primary focus is on the various topical, systemic and UV-based treatment options available and includes recomm…

medicine.medical_specialtyTuberculosisAdolescentMEDLINEDermatologyDiseaseDrug Administration Schedule030207 dermatology & venereal diseases03 medical and health sciencesPsoriatic arthritisBiological Factors0302 clinical medicinePharmacotherapyQuality of life (healthcare)PsoriasismedicineHumansPsoriasisChildBiosimilar PharmaceuticalsTonsillectomybusiness.industryVaccinationmedicine.diseaseSkin CareAnti-Bacterial AgentsFamily medicineUltraviolet TherapyDermatologic AgentsbusinessGuttate psoriasisImmunosuppressive AgentsJournal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDGReferences
researchProduct

Residual vein thrombosis and D-dimer for optimizing duration of anticoagulation in idiopathic deep vein thrombosis.

2010

Long-term anticoagulant treatment is highly effective in preventing recurrent Venous Thrombo-Embolism (VTE) in patients with idiopathic Deep Vein Thrombosis (DVT) of the lower limbs, though associated with an increased risk for major bleeding that may offset the benefits of anticoagulation. Accordingly to recent guidelines, patients with idiopathic DVT should be treated for at least 3 months and then should be evaluated for the risk-benefit ratio of long-term therapy. However, such ‘time for decision’ is often unclear and the optimal duration of VKA remains debatable. In recent studies, markers for the assessment of the individual risk for recurrent thrombosis have been proposed, which can …

medicine.medical_specialtyVitamin Kmedicine.drug_classDeep veinDrug Administration ScheduleFibrin Fibrinogen Degradation ProductsRisk FactorsNeoplasmsDrug DiscoveryD-dimerSecondary PreventionHumansMedicineUltrasonographyVenous ThrombosisPharmacologyFirst episodebusiness.industryVascular diseaseAnticoagulantAnticoagulantsresidual vein thrombosis anticoagulant therapymedicine.diseaseThrombosisSurgeryVein thrombosisVenous thrombosismedicine.anatomical_structurebusiness
researchProduct

In vivo angiotensin I-converting enzyme inhibition by long-term intake of antihypertensive lactoferrin hydrolysate in spontaneously hypertensive rats

2013

Abstract We evaluated the effect of the long-term intake of a bovine lactoferrin hydrolysate enriched in low molecular weight peptides (LFH  in vivo mechanism of action. Male spontaneously hypertensive rats received tap water (negative control), captopril (positive control, 76 mg/kg/day), LFH  in vivo mechanism for the antihypertensive effect of long-term oral administration of LFH

medicine.medical_specialtybiologyChemistryLactoferrinCaptoprilHydrolysateSpontaneously hypertensive ratEndocrinologyMechanism of actionOral administrationIn vivoInternal medicineRenin–angiotensin systemmedicinebiology.proteinmedicine.symptomFood Sciencemedicine.drugFood Research International
researchProduct

Effects of repeated treatments with an extract ofGinkgo biloba (EGb 761) and bilobalide on glucose uptake and glycogen synthesis in rat erythrocytes:…

1994

The metabolic action of an extract of Ginkgo biloba (EGb 761) has been examined in an ex vivo study of rat erythrocytes. Oral administration of EGb 761 (100 mg/kg/day) for 5 days to Wistar rats caused an increase in the in vitro uptake of glucose by erythrocytes, especially in high-glucose (13.32 mM) medium, an effect that was associated with an increase in intracellular energy metabolism and reflected as a significant reduction in free glucose concentration. In contrast, the lactate concentration of the erythrocytes and lactate release to the bathing medium were not modified. Conversion of glucose into glycogen was significantly increased in the erythrocytes of EGb 761-treated animals. Tak…

medicine.medical_specialtybiologyGlycogenGinkgo bilobaGlucose uptakeMetabolismbiology.organism_classificationchemistry.chemical_compoundEndocrinologychemistryBilobalideOral administrationInternal medicineDrug Discoverymedicinebiology.proteinGlycogen synthaseEx vivoDrug Development Research
researchProduct

Fatal Late Vitamin K-Deficiency Bleeding After Oral Vitamin K Prophylaxis Secondary to Unrecognized Bile Duct Paucity

1999

medicine.medical_specialtybusiness.industryBile ductGastroenterologyVitamin kGastroenterologymedicine.anatomical_structureEndocrinologyOral administrationInternal medicineRecien nacidoPediatrics Perinatology and Child HealthChemoprophylaxisEtiologyOral vitaminMedicinebusinessVitamin K Deficiency BleedingJournal of Pediatric Gastroenterology and Nutrition
researchProduct